ArticleInfectious diseases of poverty2026
Coverage validation survey of preventive chemotherapy for schistosomiasis in interruption of transmission districts of Ethiopia, 2025.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEthiopia bears a substantial burden of neglected tropical diseases, including schistosomiasis, which remains a major public health problem in endemic areas. Preventive chemotherapy is the main strategy for controlling and eliminating schistosomiasis. This study aimed to assess the reach of the mass drug administration program and validate the reported praziquantel coverage in interruption-of-transmission districts of Ethiopia.
methodsA community-based cross-sectional survey was conducted from 1 to 30 August 2025 in eight purposively selected districts across three Ethiopian regions targeted for schistosomiasis interventions. Using a three-stage sampling method, data were collected using WHO-standard tools via KoboToolbox. The data were analyzed using descriptive statistics, including frequencies and percentages, in SPSS version 26 to estimate program reach and survey coverage.
resultThe average programs reach (participants who offered praziquantel) was 84.2%, while surveyed coverage (participants who reported swallowing the drug) was 83.0% (95% CI: 82.7-83.3%). West Badewacho district achieved the highest survey coverage, 95.4%, while Hammer and Bena Tsemay districts achieved 92.1% and 92.4%, respectively. The lowest coverage was recorded in Menit Goldya (66.2%), Mizan (72.0%), and South Bench (72.4%). Treatment uptake among those offered praziquantel was 98.5%.
conclusionsThe survey showed that praziquantel treatment coverage was below the 95% target and the national reported average, with notable variation across districts. Surveyed coverage was largely influenced by whether the treatment was offered; districts with lower program reach consistently had lower treatment coverage. Improving the delivery and offering of praziquantel at the community level is therefore essential to increase treatment uptake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.